Kinomic profiling to predict sunitinib response of patients with metastasized clear cell Renal Cell Carcinoma
Based on kinase levels ccRCC tumors can be subdivided into 3 clusters which may reflect the aggressiveness of these tumors. The accuracy of response prediction of 61 % based on basal kinase levels is too low to justify implementation. STK assays may help to predict sunitinib toxicity and guide clinical management. Additionally, it is possible that mRCC patients with an immune kinase signature are better checkpoint inhibitor candidates, but this needs to be studied.
Authors
- Kerstin Junker (ORCID: https://orcid.org/0000-0002-0873-8128)
- Tim Eisen (ORCID: https://orcid.org/0000-0001-9663-4873)
- Lambertus A.L.M. Kiemeney (ORCID: https://orcid.org/0000-0002-2368-1326)
- Anne Y. Warren (ORCID: https://orcid.org/0000-0002-1170-7867)
- Egbert Oosterwijk (ORCID: https://orcid.org/0000-0001-5049-0018)
- Marius T. Radu
- Jeannette Oosterwijk‐Wakka (ORCID: https://orcid.org/0000-0003-4581-8167)
- Rob Ruijtenbeek
- Loes F.M. van der Zanden (ORCID: https://orcid.org/0000-0003-3914-7491)
- Ulrich Jaehde (ORCID: https://orcid.org/0000-0002-2493-7370)
- Liesbeth Houkes
Institutions
- Radboud University Nijmegen (NL)
- Carol Davila University of Medicine and Pharmacy (RO)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Radboud University Medical Center (NL)
- Central European Society for Anticancer Drug Research (AT)
- Radboud Institute for Molecular Life Sciences (NL)
- PamGene (Netherlands) (NL)
- Saarland University (DE)
Publication Details
- Journal
- Neoplasia
- Published
- 2024-12-25
- DOI
- https://doi.org/10.1016/j.neo.2024.101108
- Citations
- 3
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.26